Özet:

Aim: Soft tissue sarcomas are a type of cancer with more than 50 histological subgroups, constituting approximately 1% of malignancies. It is seen at a rate of about 5/100000. Even in patients with local disease, the survival rate is 59%; pushed clinicians to different searches. Although many studies and meta-analyses show that patients receiving adjuvant chemotherapy have a prolonged disease-free survival, there is a difference between studies on overall survival. In our study, we examined patients who received adjuvant chemotherapy in our center for soft tissue sarcoma. Material and Methods: The study was planned retrospectively. In Istanbul University Oncology Institute Medical Oncology Polyclinic; In this study, patients with soft tissue sarcoma over the age of 18 who were operated locally or locally advanced, or metastatic, who underwent both local surgery and metastasectomy and subsequently received adjuvant treatment, were recruited and the effect of adjuvant chemotherapy on the course of the disease was investigated. Results: Forty patients were included in the study. The patients were followed up for a median of 53 months (5-155). 55% of the patients are Stage 1 (10% Stage 1A, 45% Stage 1B), 15% are Stage 3 (5% Stage 3A, 10% are Stage 3B), 30% are Stage 4. Patients received a median of four cycles of adjuvant chemotherapy, and 80% of patients received Adriamycin - Ifosfamide. While the disease relapses in half of the patients, the median disease-free survival in patients with relapse is 12 months. The median overall survival of patients was 39 months. Conclusion: As a result of our study, we think that adjuvant therapy may contribute to both disease-free and total survival, and that this contribution may be in both extremity and extra-extremity soft tissue sarcomas, but we think that prospective studies with larger patient numbers would be more useful to reach a definite conclusion.

Anahtar Kelimeler: